Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $1.9 million.

  • Amicus Therapeutics' Other Operating Expenses changed N/A to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year change of. This contributed to the annual value of -$2.6 million for FY2023, which is 13961.04% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Other Operating Expenses is $1.9 million.
  • Over the past 5 years, Amicus Therapeutics' Other Operating Expenses peaked at $3.6 million during Q2 2025, and registered a low of -$3.3 million during Q3 2021.
  • For the 4-year period, Amicus Therapeutics' Other Operating Expenses averaged around -$207857.1, with its median value being -$404000.0 (2021).
  • In the last 5 years, Amicus Therapeutics' Other Operating Expenses crashed by 27370.69% in 2021 and then skyrocketed by 35222.93% in 2022.
  • Quarter analysis of 4 years shows Amicus Therapeutics' Other Operating Expenses stood at -$1.7 million in 2021, then rose by 8.65% to -$1.6 million in 2022, then decreased by 25.95% to -$2.0 million in 2023, then skyrocketed by 193.93% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $3.6 million for Q2 2025, and $1.8 million during Q1 2025.